Skip to content
Life Sciences Series B Founded 2021

Xanadu Bio

Delivery of nanoparticle system for mRNA and other payload delivery

📍 United States · Drug Delivery

Funding snapshot

Last roundSeries B
Amount$11M
Date13 August 2025

About

Delivery of nanoparticle system for mRNA and other payload delivery. The company leverages poly amine-co-esters(PACE) technology for efficient delivery of and protection from nuclease degradation for different types of nucleic acids, including mRNA targeting infectious diseases, such as COVID-19.

Latest news

No articles yet.

Raising like Xanadu Bio?

Analyze your pitch deck before your next raise.

Analyze My Deck →